Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 382
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Sijmen de Vries M.B.A., M.D. | President, CEO & Executive Director | 1,34M | S.O. | 1959 |
Mr. Jeroen Wakkerman | Chief Financial Officer | S.O. | S.O. | 1969 |
Ms. Mireille Sanders M.Sc. | Chief Operations Officer | S.O. | S.O. | 1968 |
Susanne Embleton | Investor Relations Manager | S.O. | S.O. | S.O. |
Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer | S.O. | S.O. | 1964 |
Dr. Anurag Relan M.D., MPH | Chief Medical Officer | S.O. | S.O. | 1972 |
Mr. Stephen Toor | Chief Commercial Officer & GM Americas | S.O. | S.O. | 1971 |
Dr. Alexander Breidenbach M.B.A. | Chief Business Officer | S.O. | S.O. | 1964 |
Dr. Bruno M. L. Giannetti | Consultant | S.O. | S.O. | 1952 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
L’ISS Governance QualityScore de Pharming Group N.V. en date du 1 mai 2024 est 1. Les scores principaux sont Audit : 7; Société : 1; Droits des actionnaires : 3; Compensation : 1.